alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                           8,121
<SECURITIES>                                    26,728
<RECEIVABLES>                                   22,565
<ALLOWANCES>                                     (709)
<INVENTORY>                                     21,856
<CURRENT-ASSETS>                                65,641
<PP&E>                                          11,785
<DEPRECIATION>                                 (5,446)
<TOTAL-ASSETS>                                  98,276
<CURRENT-LIABILITIES>                           12,623
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            24
<OTHER-SE>                                      84,951
<TOTAL-LIABILITY-AND-EQUITY>                    98,276
<SALES>                                         71,439
<TOTAL-REVENUES>                                71,439
<CGS>                                           27,498
<TOTAL-COSTS>                                   27,498
<OTHER-EXPENSES>                                34,282
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 478
<INCOME-PRETAX>                                 11,359
<INCOME-TAX>                                     (534)
<INCOME-CONTINUING>                             11,893
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    11,893
<EPS-PRIMARY>                                     0.50
<EPS-DILUTED>                                     0.47
        

</TABLE>
<PAGE>   1
                                 UNITED STATES


                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

                                 DATE OF REPORT
                                DECEMBER 5, 1997

                         AMAZON NATURAL TREASURES, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                     NEVADA
                 (STATE OR OTHER JURISDICTION OF INCORPORATION)


       33-26109                                          87-0460880
(COMMISSION FILE NUMBER)                              (IRS EMPLOYER ID)

                            4011 WEST OQUENDO UNIT C
                             LAS VEGAS NEVADA 89118
             (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES AND ZIP CODE)


                                 (702) 795-4333
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
<PAGE>   2
                       SECURITIES AND EXCHANGE COMMISSION

                                    FORM 8-K



ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.

     On December 5, 1997, Amazon Natural Treasures, Inc. (The Company) was
informed that Mr. Darrell Schvaneveldt resigned as the Company's auditor.

     At no time has anyone from Mr. Schvaneveldt's office sent any
correspondence concerning his impending resignation and we had no reason to
believe that he had resigned.



                                   SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.




                                   AMAZON NATURAL TREASURES, INC.
                                   (Registrant)


Date:  December 11, 1997



                                   By: /s/ MICHAEL A. SYLVER
                                      ---------------------------
                                      Michael A. Sylver
                                      President
<TABLE> <S> <C>

<ARTICLE>                     5
<CIK>                         0000813621
<NAME>                        AMCOL International Corporation
<MULTIPLIER>                                   1,000
<CURRENCY>                                     USD

<S>                                            <C>
<PERIOD-TYPE>                                  9-MOS
<FISCAL-YEAR-END>                              DEC-1-2000
<PERIOD-START>                                 JAN-1-2000
<PERIOD-END>                                   SEP-30-2000
<EXCHANGE-RATE>                                1.00
<CASH>                                         5,069
<SECURITIES>                                   192,084
<RECEIVABLES>                                  63,780
<ALLOWANCES>                                   2,597
<INVENTORY>                                    21,883
<CURRENT-ASSETS>                               303,032
<PP&E>                                         196,013
<DEPRECIATION>                                 114,557
<TOTAL-ASSETS>                                 408,767
<CURRENT-LIABILITIES>                          209,059
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       320
<OTHER-SE>                                     0
<TOTAL-LIABILITY-AND-EQUITY>                   408,767
<SALES>                                        214,848
<TOTAL-REVENUES>                               214,848
<CGS>                                          162,026
<TOTAL-COSTS>                                  203,804
<OTHER-EXPENSES>                               374
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             2,774
<INCOME-PRETAX>                                14,961
<INCOME-TAX>                                   6,178
<INCOME-CONTINUING>                            9,116
<DISCONTINUED>                                 7,766
<EXTRAORDINARY>                                313,621
<CHANGES>                                      0
<NET-INCOME>                                   330,503
<EPS-BASIC>                                    12.11
<EPS-DILUTED>                                  11.27


</TABLE>
H. Res. 233 

In the House of Representatives, U. S., 

March 29, 2017. 

Resolved, That upon adoption of this resolution it shall 

be in order to consider in the House the bill (H.R. 1431) to 

amend the Environmental Research, Development, and Demonstration Authorization Act of 1978 to provide for Scientific 

Advisory Board member qualifications, public participation, 

and for other purposes. All points of order against consideration of the bill are waived. The bill shall be considered as 

read. All points of order against provisions in the bill are 

waived. The previous question shall be considered as ordered 

on the bill and on any amendment thereto to final passage 

without intervening motion except: (1) one hour of debate 

equally divided and controlled by the chair and ranking minority member of the Committee on Science, Space, and 

Technology; and (2) one motion to recommit. 

Attest: 

Clerk.
**EXHIBIT
      32.2**





**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION 906
      OF THE SARBANES-OXLEY ACT OF 2002**








In
      connection with the accompanying Quarterly Report on Form 10-Q of Southwall
      Technologies Inc. (the “Company”), for the quarter ended October 2, 2005, as
      filed with the Securities and Exchange Commission on the date hereof (the
“Report”), I, Sylvia Kamenski, the Acting Chief Financial Officer of the
      Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted
      pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
      that:




1)
              the
                  Report fully complies with the requirements of Section 13(a) or
                  15(d) of
                  the Securities Exchange Act of 1934;
                  and
  2)
              the
                  information contained in the Report fairly presents, in all material
                  respects, the financial condition and results of operations of
                  the
                  Company.




November
                15, 2005
            By:
            /s/
                Sylvia KamenskiSylvia
                Kamenski*Acting
                Chief Financial Officer*








A
      signed
      original of this written statement required by Section 906, or other
      document authenticating, acknowledging or otherwise adopting the signature
      that
      appears in typed form within the electronic version of this written statement
      required by Section 906, has been provided to the Company and will be
      retained by the Company and furnished to the Securities and Exchange Commission
      or its staff upon request.





In
      accordance with Item 601 of Regulation S-K, this certification is being
“furnished” as Exhibit 32.2 to the Company's quarterly report and shall not
      be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
      of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that
      section, nor shall it be deemed incorporated by reference in any filing under
      the Securities Act of 1933 or the Exchange Act, except as expressly set forth
      by
      specific reference in such a filing.
#### In re STATE ST. IN CITY OF ALBANY.

(Supreme Court, Appellate Division, Third Department.

July 1, 1914.)

In the matter of the acquisition of lands for the improvement of State Street, from Broadway to the pier, in which Alexander Friedlander, appeals.

No opinion. Order unanimously affirmed, with costs.
IV 

115TH CONGRESS 

1ST SESSION H. RES. 26 

Expressing the sense of the House of Representatives that the provisions 

of the Patient Protection and Affordable Care Act that restored the 

original black lung benefits eligibility requirements should not be reduced 

but should be preserved and protected. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 5, 2017 

Mr. JENKINS of West Virginia (for himself, Mr. ROGERS of Kentucky, Mr. 

MCKINLEY, Mr. GRIFFITH, and Mr. MOONEY of West Virginia) submitted the following resolution; which was referred to the Committee on 

Education and the Workforce 

RESOLUTION 

Expressing the sense of the House of Representatives that 

the provisions of the Patient Protection and Affordable 

Care Act that restored the original black lung benefits 

eligibility requirements should not be reduced but should 

be preserved and protected. 

Whereas men and women who spend their lives mining coal 

deserve the black lung benefits afforded them through 

the Black Lung Benefits Act; 

Whereas these critical benefits are important for thousands 

of men and women across the United States; 


smartinez on DSK3GLQ082PROD with BILLS
2 

•HRES 26 IH 

Whereas, since 1969, black lung benefits have been guaranteed by the Federal Government and have provided assistance for miners and their widows; 

Whereas, in 1981, the Black Lung Benefits Act was amended 

tightening eligibility requirements and eliminating two 

provisions regarding the entitlement benefits of coal minors and survivors alike; 

Whereas the Black Lung Benefits Act was amended by the 

Patient Protection and Affordable Care Act to restore 

provisions similar to those in the original Black Lung 

Benefits Act, providing equity for certain eligible survivors; 

Whereas these restored black lung benefits are critical for the 

widows and widowers of miners; 

Whereas the leadership of the House of Representatives and 

the Senate have indicated that Congress will act to repeal 

the Patient Protection and Affordable Care Act in the 

115th Congress; and 

Whereas President-elect Donald Trump has indicated that he 

would sign a repeal of the Patient Protection and Affordable Care Act: Now, therefore, be it 

1 Resolved, That it is the sense of the House of Rep2 resentatives that in the event that Congress drafts provi3 sions to amend or repeal the Patient Protection and Af4 fordable Care Act, the provisions of such Act that restored 

5 the original black lung benefits eligibility requirements 

6 should not be reduced but should be preserved and pro7 tected. 

Æ 


smartinez on DSK3GLQ082PROD with BILLS
IV 

House Calendar No. 225 

109TH CONGRESS 

2D SESSION H. RES. 996 

[Report No. 109–646] 

Providing for consideration of the resolution (H. Res. 994) expressing the 

sense of the House of Representatives on the fifth anniversary of the 

terrorist attacks launched against the United States on September 11, 

2001. 

IN THE HOUSE OF REPRESENTATIVES 

SEPTEMBER 12, 2006 

Mr. SESSIONS, from the Committee on Rules, reported the following resolution; which was referred to the House Calendar and ordered to be printed 

RESOLUTION 

Providing for consideration of the resolution (H. Res. 994) 

expressing the sense of the House of Representatives 

on the fifth anniversary of the terrorist attacks launched 

against the United States on September 11, 2001. 

1 Resolved, That upon the adoption of this resolution 

2 it shall be in order without intervention of any point of 

3 order to consider in the House the resolution (H. Res. 

4 994) expressing the sense of the House of Representatives 

5 on the fifth anniversary of the terrorist attacks launched 


pwalker on PRODPC60 with BILLS
2 

HRES 996 RH 

1 against the United States on September 11, 2001. The 

2 resolution shall be considered as read. The previous ques3 tion shall be considered as ordered on the resolution and 

4 preamble to final adoption without intervening motion or 

5 demand for division of the question except: (1) four hours 

6 of debate equally divided and controlled by the Majority 

7 Leader and Minority Leader or their designees; and (2) 

8 one motion to recommit which may not contain instruc9 tions. 

10 SEC. 2. During consideration of House Resolution 

11 994 pursuant to this resolution, notwithstanding the oper12 ation of the previous question, the Chair may postpone 

13 further consideration of the resolution to a time des14 ignated by the Speaker. 


pwalker on PRODPC60 with BILLS

pwalker on PRODPC60 with BILLS
House Calendar No. 225 

109TH CONGRESS 

2D SESSION H. RES. 996 

[Report No. 109

–646] 

RESOLUTION 

Providing for consideration of the resolution (H. 

States on September 11, 2001. terrorist attacks launched against the United Representatives on the fifth anniversary of the Res. 994) expressing the sense of the House of 

SEPTEMBER 12, 2006 

Referred to the House Calendar and ordered to be 

printed 


pwalker on PRODPC60 with BILLS
## COURT OF APPEALS

SECOND DISTRICT OF TEXAS

FORT WORTH

NO. 02

- 16

- 00360

- CV

In re B.L. §

§

§

§

§ Original Proceeding

From the 233rd District Court

of Tarrant County (233

- 515485

- 12)

November 17, 2016

Opinion by Justice Walker



### JUDGMENT

This court has considere d the petition for writ of habeas corpus filed by

relator B.L. We grant the petition for writ of habeas corpus in part and deny in

part. We grant the relief sought by relator to the extent we declare the January 5,

2016 order of commitment, the February 17, 2016 order for issuance of a capias,

and a capias issued February 17, 2016 void. All other relief sought in relator’s

petition for writ of habeas corpus is denied.

It is further ordered that all parties shall bear their own costs of this

proceeding, for which let execution issue.

SECOND DISTRICT COURT OF APPEALS

By

_ /s/ Sue Walker

___________________ Justice Sue Walker
Editorial Note on Part 170
Editorial Note: Nomenclature changes to part 170 appear at 66 FR 56035, Nov. 6, 2001, and 69 FR 13717, Mar. 24, 2004.

§ 170.102 Confidentiality of information related to premarket notification for a food contact substance (FCN). ( a ) During the 120-day period of the Food and Drug Administration (FDA) review of an FCN, FDA will not disclose publicly any information in that FCN.
( b ) FDA will not disclose publicly the information in an FCN that is withdrawn prior to the completion of FDA's review.
( c ) Once FDA completes its review of an FCN, the agency will make its conclusion about the FCN publicly available. For example, if FDA objects to a notification 90 days after the date of receipt, the agency would make available its objection at that time.
( d ) By submitting an FCN to FDA, the manufacturer or supplier waives any claim to confidentiality of the information required to adequately describe the food contact substance and the intended conditions of use that are the subject of that FCN.
( e ) The following data and information are available for public disclosure, unless extraordinary circumstances are shown, on the 121st day after receipt of the notification by FDA, except that no data or information are available for public disclosure if the FCN is withdrawn under § 170.103; and on the date of publication in the Federal Register of an FDA determination that an FCN is no longer effective. ( 1 ) All safety and functionality data and information submitted with or incorporated by reference into the notification, or submitted in reference to an effective FCN. Safety and functionality data include all studies and tests of a food contact substance on animals and humans and all studies and tests on a food contact substance for establishing identity, stability, purity, potency, performance, and usefulness.
( 2 ) A protocol for a test or study, unless it is exempt from disclosure under § 20.61 of this chapter.
( 3 ) A list of all ingredients contained in a food contact substance, excluding information that is exempt from disclosure under § 20.61 of this chapter. Where applicable, an ingredient list will be identified as incomplete.
( 4 ) An assay method or other analytical method, unless it serves no regulatory or compliance purpose and is exempt from disclosure under § 20.61 of this chapter.
( 5 ) All correspondence and written summaries of oral discussions relating to the notification or to FDA's determination that an FCN is no longer effective, except information that is exempt under § 20.61 of this chapter.
( 6 ) All other information not subject to an exemption from disclosure under subpart D of part 20 of this chapter.
[67 FR 35729, May 21, 2002, as amended by 89 FR 20315, Mar. 22, 2024]
H. Res. 857

In the House of Representatives, U.S., 

June 12, 2006.

Resolved, That upon adoption of this resolution it shall 

be in order to consider the conference report to accompany 

the bill (H.R. 4939) making emergency supplemental appropriations for the fiscal year ending September 30, 2006, and 

for other purposes. All points of order against the conference 

report and against its consideration are waived. The conference report shall be considered as read.

Attest: 

Clerk.
Editorial Note on Part 10
Editorial Note: Nomenclature changes to part 10 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45064, July 14, 2023.

§ 10.100 Public calendar. ( a ) *Public calendar.* A public calendar will be prepared and made publicly available by FDA each week showing, to the extent feasible, significant events of the previous week, including significant meetings with persons outside the executive branch, that involve the representatives of FDA designated under paragraph (c) of this section. ( 1 ) Public calendar entries will include: ( i ) Significant meetings with members of the judiciary, representatives of Congress, or staffs of congressional committees when the meeting relates to a pending court case, administrative hearing, or other regulatory action or decision;
( ii ) Significant meetings, conferences, seminars, and speeches; and
( iii ) Social events sponsored by the regulated industry.
( 2 ) The public calendar will not include reports of meetings that would prejudice law enforcement activities (e.g., a meeting with an informant) or invade privacy (e.g., a meeting with a candidate for possible employment at FDA), meetings with members of the press, or meetings with onsite contractors.
( b ) *Calendar entries.* The calendar will specify for each entry the date, person(s), and subject matter involved. If a large number of persons are in attendance, the name of each individual need not be specified. When more than one FDA representative is in attendance, the most senior agency official will report the meeting on the public calendar.
( c ) *Affected persons.* The following FDA representatives are subject to the requirements of this section: ( 1 ) Commissioner of Food and Drugs.
( 2 ) Senior Associate Commissioners.
( 3 ) Deputy Commissioners.
( 4 ) Associate Commissioner for Regulatory Affairs.
( 5 ) Center Directors.
( 6 ) Chief Counsel for the Food and Drug Administration.
( d ) *Public display.* The public calendar will be placed on public display at the following locations: ( 1 ) Dockets Management Staff.
( 2 ) Office of the Associate Commissioner for Public Affairs.
( 3 ) The FDA home page, to the extent feasible.
[66 FR 6468, Jan. 22, 2001]
#### § 1002.2 [Reserved]
§ 1.72 Data elements that must be submitted in ACE for articles regulated by FDA. *General.* When filing an entry in ACE, the ACE filer shall submit the following information for food contact substances, drugs, biological products, HCT/Ps, medical devices, veterinary devices, radiation-emitting electronic products, cosmetics, and tobacco products. ( a ) *Product identifying information* for the article that is being imported or offered for import. This consists of: ( 1 ) *FDA Country of Production,* which is the country where the article was last manufactured, processed, or grown (including harvested, or collected and readied for shipment to the United States). The FDA Country of Production for an article that has undergone any manufacturing or processing is the country where that activity occurred provided that the manufacturing or processing had more than a minor, negligible, or insignificant effect on the article.
( 2 ) *The Complete FDA Product Code,* which must be consistent with the invoice description of the product.
( 3 ) *The Full Intended Use Code.*
( b ) *Importer of record contact information,* which is the telephone and email address of the importer of record.
[81 FR 85870, Nov. 29, 2016, as amended at 87 FR 62984, Oct. 18, 2022]